View in EDS HTML Full Text PDF Full Text

Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks.

Saved in:

Bibliographic Details
Title:	Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks.
Authors:	Blauvelt, Andrew¹ (AUTHOR), Papp, Kim^2,3 (AUTHOR), Trivedi, Mona⁴ (AUTHOR), Barragan, Carolina⁴ (AUTHOR), Chow, Vincent⁴ (AUTHOR), Mytych, Daniel T⁴ (AUTHOR), Yamauchi, Paul⁵ (AUTHOR), Crowley, Jeff⁶ (AUTHOR), Franklin, Janet⁴ (AUTHOR)
Source:	British Journal of Dermatology. May2025, Vol. 192 Issue 5, p826-836. 11p.
Database:	Academic Search Ultimate
Full text is not displayed to guests. Login for full access.

Description
ISSN:	00070963
DOI:	10.1093/bjd/ljae402